
-
Schrodinger Inc NASDAQ:SDGR Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Location: 1540 Broadway, 24th Floor, NY, 10036, US | Website: www.schrodinger.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.438B
Cash
352.1M
Avg Qtr Burn
-39.34M
Short % of Float
16.14%
Insider Ownership
2.49%
Institutional Own.
97.93%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SGR-3515 (Wee1/Myt1 inhibitor) Details Solid tumor/s | Phase 1 Data readout | |
SGR-2921 (CDC7 inhibitor) Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 1 Data readout | |
SGR-1505 (MALT1 inhibitor) Details Cancer, B-cell malignancies | Phase 1 Data readout |